About Us
Welcome to the website of Eisai (Singapore) Pte. Ltd., a pharmaceutical subsidiary of Eisai Co., Ltd. based in Tokyo, Japan.
Parent Company
Eisai Co., Ltd. was founded in Japan in 1941 as Nihon Eisai Co., Ltd. To this day, Eisai Co., Ltd. is one of the few Japanese pharmaceutical companies to undertake aggressive global expansion through substantial infrastructure investments in its foreign affiliates. These affiliates conduct research and development, manufacturing, and sales and marketing in the United States, Europe and Asia.
Eisai has more than 10,000 employees worldwide and is a publicly traded company whose stock trades on the Tokyo Stock Exchange and is listed in the United States.
Corporate Mission
Our human health care (hhc) mission, the desire to contribute to patients, is our corporate concept and the core of our business.
"We give first thought to patients and the people in the daily living domain, and increase the benefits that healthcare provides to them as well as meet their diversified healthcare needs worldwide."
Corporate Objective
A human health care company capable of making a meaningful contribution under any health care system while observing the highest legal and ethical standards in business activities.
Eisai’s hhc Philosophy
Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, treatment and care for the health and well-being of people worldwide. Our company’s hhc mission symbol is derived from the letters in Florence Nightingale’s signature. Following the example set by this famed healthcare pioneer, who devoted her life to caring for others yet never lost sight of the importance of listening to her patients, Eisai marshals its talents to explore new therapeutic approaches that help address two key goals: meeting the medical needs of patients and their families, and improving their quality of life.
News Release
“LEQEMBI®” (Lecanemab) Approved for Slowing the Progression of Early Alzheimer’s Disease in Singapore
Singapore, May 28, 2025 – Eisai (Singapore) Pte Ltd (Managing Director: Celine Ting) announced that Health Sciences Authority (HSA) of Singapore has approved LEQEMBI® (lecanemab)1, a globally recognized innovation for slowing the progression of Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease.
Lecanemab is the first approved Aβ monoclonal antibody that preferentially binds and clears toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ aggregates).2-6 Protofibrils are a key toxic form of Aβ that accumulate in the brain and cause neuronal injury.3-9
The approval of LEQEMBI® is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI® met its primary endpoint and all key secondary endpoints with statistically significant results.2,10
Approximately 92,000 people in Singapore are estimated to suffer from dementia, with that number projected to rise to approximately 152,000 by 2030.11 AD accounts for 60-70% of all dementia diagnoses worldwide.12
Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. In Singapore, Eisai will promote the medicine as it is the Product Registrant holder.
MEDIA CONTACTS
Eisai Singapore
Tel: +65-62966977
Our Products
Eisai has positioned neurology and oncology as its therapeutic areas of focus, where there are many diseases for which adequate treatments have yet to be established. In order to fulfill patients’ unmet needs, Eisai sets out a goal to be a “Medico Societal Innovator” or in other words, “a company that changes society through creating medicines and providing solutions”.
Neurology
Gastrointestinal/Others
Oncology
